Ken Griffin’s Citadel Boosts Stakes in Coca-Cola and Medtronic Amid Market Volatility
Billionaire investor Ken Griffin's Citadel hedge fund made significant moves in Q2, increasing its stake in Coca-Cola by nearly 2,000% and Medtronic by 13%. The fund's historical outperformance makes these allocations noteworthy for dividend-focused investors.
Coca-Cola's resilience as a consumer staples leader and its adaptive product strategy position it as a defensive play. Medtronic's medical technology portfolio offers stability in healthcare markets. Neither stock carries direct cryptocurrency exposure, but Griffin's allocations signal a broader institutional preference for cash-flowing assets during uncertain macroeconomic conditions.